Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1718)	10/25/2006 11:01:09 AM
From: tuck	Read Replies (1) \| Respond to of 1826

I have seen the report, and what he says is reasonable, but . . . if AMTech is overly bearish, Aschoff is just an a**hole: Message 22078480 Cheers, Tuck

To: Icebrg who wrote (1718)	11/7/2006 9:30:53 PM
From: Icebrg	Read Replies (1) \| Respond to of 1826

MGI Pharma downgraded to "hold" Tuesday, November 07, 2006 6:40:34 AM ET When2Trade Group NEW YORK, November 7 (newratings.com) - Analysts at Why2Trade Group downgrade MGI Pharma Inc (MOGN.NAS) from "strong buy" to "hold." In a research note dated November 5 and published this morning, the analysts mention that the downgrade in the rating is based on valuation. The analysts believe that MGI Pharma’s stock is fully valued at present, in view of the anticipated modest EPS growth in the forthcoming few years, slowdown in Aloxi sales, expected impact of competition on future sales of Dacogen and cost of recent acquisitions.